

57th Annual Meeting of the Japanese Society of Neurology

[Day 4] May 21 (Sat.)

Symposium Educational Session Oral Session Social Event

E English Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Kobe International Exhibition Hall	Hall No.2 Building 1F	Room 1 Convention Hall				Oral Session O-41 CVD (Endovascular therapy)	LS-39 Mitsubishi Tanabe Pharma Corporation										
	Hall No.1 Building 2F	Room 2 Exhibition Hall A	Symposium 17 Messages from key persons of government agencies; Expectation for future neurological disease researches			Oral Session O-42 Dementia (Clinical research 2 (Japanese))	LS-40 GlaxoSmithKline K.K.			Symposium 18 Improving Clinical Trials in ALS: Airie House Guidelines 2016 Workshop							
		Room 3 Exhibition Hall B				Oral Session O-43 Neurorehabilitation											
	Hall No.2 Building 2F	Room 4 Room 3A	Lecture Marathon (Prof. Masakuni Kameyama Memorial Lecture)	LM-12	LM-13	Oral Session O-44 Clinical Neurophysiology	LS-41 Takeda Pharmaceutical Company Limited										
	Hall No.2 Building 2F	Room 5 Room 2A			Students and Junior Residents Oral Session 01			LS-42 Sumitomo Dainippon Pharma Co., Ltd.									
	Hall No.2 Building 2F	Room 6 Room 3B			Students and Junior Residents Oral Session 02		Students and Junior Residents Oral Session 03 Nominees for the Best Presentation Award										
Kobe Portopia Hotel	Main Building B 1F	Room 7 Kairaku 1	Symposium 18 Clinicopathological association of PSP/CBD			Oral Session O-45 PD/PSP (Clinical research)	LS-43 Pfizer Japan Inc.										
		Room 8 Kairaku 2	Toward Treatable Neurology 08 Tomorrow's neurological therapy - almost there!			Oral Session O-46 Dementia (Pathophysiology)											
		Room 9 Kairaku 3	Toward Treatable Neurology 09 Drug development and future medicine in cerebral infarction			Oral Session O-47 CVD (Clinical research)											
Kobe International Conference Center	1F	Room 10 Main Hall	Neuroscience Frontier Symposium 02 Therapeutic strategies, mechanisms of spreading of α -synuclein, and biomarkers of Parkinson's disease			Oral Session O-48 Parkinsonism (Clinical and imaging research)	LS-44 Kyowa Hakkō Kirin Co., Ltd.		Late Breaking Symposium	Special Program How should we renew Japanese Neurology Specialist System?	Closing Ceremony						
	3F	Room 11 International Conference Hall	Toward Treatable Neurology 10 Role of neurorehabilitation in cure oriented neurology. Can neurorehabilitation play a role in disease modifying therapy?							Symposium 20 Novel therapeutic approach in neurorehabilitation							
	3F	Room 12 Reception Hall															
	4F	Room 13 Meeting Room 401 + 402															
	5F	Room 14 Meeting Room 501	Hot Topics 18 Developments of Pathogenic Research in Demyelinating Diseases			Oral Session O-49 HAM/Neuroinflammatory diseases	LS-45 Janssen Pharmaceutical K.K.										
	Room 15 Meeting Room 502	Symposium for Encouragement of Study Abroad Let's study abroad: the dream of studying abroad for medical students and residents			Oral Session O-50 Ataxia/Spastic paraplegia (Genetics)	LS-46 Eisai Co., Ltd.											
Exhibition Hall	1	Poster Session Hall No.3 Building		Poster preparation			Poster Round		Poster Session	Poster Removal							